Loading
AMEXHealthcareMedical - Care Facilities
Latest quote
$4.28
+$0.04 · +0.94%
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Previous close
$4.28
+$0.04 · +0.94%
Regular session · ET · Market data may be delayed.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Day range
Current $4.28
52-week range
Current $4.28
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
40
Bearish
Risk
64
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Day range
Current $4.28
52-week range
Current $4.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 31.57M USD | 31.99M USD | 31.34M USD | 30.34M USD | 28.88M USD |
| Cost of goods sold | 7.38M USD | 7.95M USD | 8.44M USD | 8.79M USD | 8.99M USD |
| Gross profit | 24.19M USD | 24.04M USD | 22.9M USD | 21.54M USD | 19.9M USD |
| Research and development | 376.26K USD | 1.24M USD | 1.17M USD | 384.79K USD | 49.87K USD |
| Selling, general, and administrative | 18.22M USD | 18.52M USD | 17.12M USD | 15.58M USD | 14.63M USD |
| Operating expenses | 19.35M USD | 20.56M USD | 35.21M USD | 17.52M USD | 15.88M USD |
| Interest expense | 2.07M USD | 1.86M USD | 1.24M USD | 1.52M USD | 1.38M USD |
| Depreciation and amortization | 1.37M USD | 483.52K USD | 1.71M USD | 1.81M USD | 1.33M USD |
| Operating income | 4.84M USD | 3.48M USD | −12.3M USD | 4.02M USD | 4.02M USD |
| Net income | −2.43M USD | 402.1K USD | −9.52M USD | 2.77M USD | 2.08M USD |
Company facts updated Sep 7, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$8.50
98.60% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 21, 2025 | $0.15Quarterly | May 21, 2025 | May 30, 2025 |
Dividend | Feb 14, 2025 | $0.25Quarterly | Feb 14, 2025 | Feb 28, 2025 |
Dividend | Nov 15, 2024 | $0.25Annual | Nov 15, 2024 | Nov 29, 2024 |
Dividend | Sep 1, 2022 | $0.90Special | Sep 2, 2022 | Sep 9, 2022 |
Ex-dividend May 21, 2025
$0.15
Quarterly
Record May 21, 2025 · Payment May 30, 2025
Ex-dividend Feb 14, 2025
$0.25
Quarterly
Record Feb 14, 2025 · Payment Feb 28, 2025
Ex-dividend Nov 15, 2024
$0.25
Annual
Record Nov 15, 2024 · Payment Nov 29, 2024
Ex-dividend Sep 1, 2022
$0.90
Special
Record Sep 2, 2022 · Payment Sep 9, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
